Isaac Francis

Charger Metals (ASX:CHR) has lodged a mining lease application (MLA 63/691) for the development of its 100% owned Medcalf Lithium deposit and Medcalf West exploration target.

DroneShield (ASX:DRO) has secured a $8.2 million contract for delivery to a western military end-customer through an in-country reseller.

GATX Corp. (NYSE:GATX) said it and Brookfield Infrastructure Partners L.P. (NYSE:BIP) have received all required regulatory approvals to complete their previously announced transaction to acquire Wells Fargo’s rail operating lease portfolio

Mereo BioPharma (NASDAQ:MREO)  said Phase 3 trials of setrusumab (UX143) in osteogenesis imperfecta failed to meet their primary endpoints, dealing a setback to the late-stage program as the company moves to cut spending and reassess priorities.

Crypto exchange-traded products recorded $446 million in net outflows during the final full trading week of Christmas, reflecting fragile sentiment across digital asset markets.

SELLAS Life Sciences (NYSE:SLS) said it is approaching the final analysis milestone in its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in acute myeloid leukemia, following an aggregate event count update from its contract research organization.

Genmab (NASDAQ:GMAB) said it will discontinue further clinical development of acasunlimab, as the company sharpens its focus on the most value-creating opportunities in its late-stage portfolio amid an increasingly competitive landscape.

Theriva Biologics (NYSE:TOVX) said it has received Scientific Advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on the design of a proposed Phase 3 trial evaluating VCN-01 in combination with gemcitabine and nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Bluejay Diagnostics (NASDAQ:BJDX) said it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6) for its Symphony™ cartridge program, marking a development milestone for the diagnostic platform.

ECARX (NASDAQ:ECX) said it has entered into a share subscription agreement with Lotus Technology (NASDAQ:LOT) to invest $23 million through a private placement, deepening their strategic collaboration in automotive software and computing platforms.